HI-Bio
South San Francisco
About HI-Bio
Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases. The company's lead product, felzartamab, is a fully human anti-CD38 monoclonal antibody that has been shown in clinical studies to deplete CD38+ cells that include plasma cells and natural killer, or NK, cells which may allow for applications that improve clinical outcomes in a broad range of immune-mediated diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $215.0M
- Funding stage: M&A
- Last round: Series B (Jan 2024)
- Website: hibio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Life Science, Medical, Product Research, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/hi-bio-18359 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.